NUV-868 is a small molecule commercialized by Nuvation Bio, with a leading Phase II program in Triple-Negative Breast Cancer (TNBC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of NUV-868’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for NUV-868 is expected to reach an annual total of $183 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NUV-868 is under development for the treatment of acute myeloid leukemia and advanced solid tumors including ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, metastatic castration resistant prostate cancer (mCRPC) and triple negative breast cancer (TNBC). It is administered through oral route. The drug candidate targets bromodomain-containing protein 4 (BRD4).
Nuvation Bio Overview
Nuvation Bio is a biotechnology company developing proprietary therapies focused on oncology. The companies proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company is headquartered in New York City, New York, the US.
The operating loss of the company was US$119.7 million in FY2022, compared to an operating loss of US$93.3 million in FY2021. The net loss of the company was US$104.2 million in FY2022, compared to a net loss of US$86.9 million in FY2021.
For a complete picture of NUV-868’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.